Command Palette

Search for a command to run...

Clinical Trials · NCT05959096

A Study of LY3437943 in Healthy Participants With a High Body Mass Index

CompletedPhase 1Retatrutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
85
Start date
Jul 2023
Locations
1 site, United States
Primary endpoint
Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943
View Retatrutide compound reference